Galderma

Galderma

Galderma Group AG was carved out of Nestlé in 2019, when the Swiss food giant sold the skincare unit to an EQT-led consortium for CHF 10.2 billion. Under the ownership of EQT, GIC, PSP Investments, and the Abu Dhabi Investment Authority, the company sharpened its exclusive focus on the science of skin, shedding its prior identity as a consumer-health subdivision. CEO Flemming Ørnskov, a former Shire executive who joined the board in 2019 and became CEO in 2021, drove the operational separation and oversaw the March 2024 initial public offering on the SIX Swiss Exchange — the largest Swiss listing in decades — before the firm joined the Swiss Market Index in September 2024. The firm operates across three product categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Injectable Aesthetics, led by the hyaluronic-acid fillers Restylane and Sculptra and the neuromodulator Alluzience, represents the growth engine; several fillers have been cleared in China and the U.S. in recent cycles. The skincare portfolio includes Cetaphil and Alastin, while the therapeutics pipeline addresses acne, rosacea, and prurigo nodularis. Galderma runs a direct commercial infrastructure spanning over 90 countries with manufacturing sites in Sweden, France, Brazil, and Canada. Post-IPO, the EQT-led investor group retained majority ownership, with proceeds used to deleverage the balance sheet and fund R&D. The firm has not publicly disclosed total assets under management or a deployment figure in the private-fund sense — it is an operating company, not a financial-institution fund. A notable governance marker: the board includes representatives from each of the major consortium members, and the company reports as a public entity with an investor relations function matching SIX Swiss Exchange standards. Galderma occupies a structural niche few peer companies can replicate: it is a single-category, publicly traded pharmaceutical company with a controlling private-equity shareholder base. This hybrid governance means management answers to public-market investors for quarterly results while retaining strategic direction from a consortium that still holds roughly two-thirds of the equity. The operating-company architecture — manufacturing its own products, selling them through its own commercial teams, and running its own clinical trials — means there is no fund-level liquidity gate or deployment pace an allocator would underwrite. For institutional investors evaluating exposure, Galderma functions as a listed-equity opportunity in the dermatology therapeutic category, not a commitment to a pooled vehicle.